U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Renal and Urinary Disorders, CTCAE

MedGen UID:
1636208
•Concept ID:
C4553093
•
Finding

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRenal and Urinary Disorders, CTCAE

Professional guidelines

PubMed

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T, Yazawa M, Yamamoto R, Okada N, Mori K, Yamada H, Kuwabara T, Yonezawa A, Fujimaru T, Kawano H, Yokoi H, Doi K, Hoshino J, Yanagita M
Int J Clin Oncol 2023 Oct;28(10):1259-1297. Epub 2023 Jun 29 doi: 10.1007/s10147-023-02372-4. PMID: 37382749
Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H
Clin Exp Nephrol 2017 Aug;21(4):732-740. Epub 2016 Aug 26 doi: 10.1007/s10157-016-1327-z. PMID: 27565169
Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer.
Kobayashi S, Ueno M, Ohkawa S, Irie K, Goda Y, Morimoto M
Oncology 2014;87(1):30-9. Epub 2014 Jun 25 doi: 10.1159/000362604. PMID: 24969038

Recent clinical studies

Etiology

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T, Yazawa M, Yamamoto R, Okada N, Mori K, Yamada H, Kuwabara T, Yonezawa A, Fujimaru T, Kawano H, Yokoi H, Doi K, Hoshino J, Yanagita M
Int J Clin Oncol 2023 Oct;28(10):1259-1297. Epub 2023 Jun 29 doi: 10.1007/s10147-023-02372-4. PMID: 37382749
Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers.
Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C, Casuscelli J
J Geriatr Oncol 2020 Sep;11(7):1061-1066. Epub 2020 Jun 18 doi: 10.1016/j.jgo.2020.06.012. PMID: 32565147
A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P
J Oncol Pharm Pract 2019 Jun;25(4):875-883. Epub 2018 May 3 doi: 10.1177/1078155218771461. PMID: 29722605
Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H
Clin Exp Nephrol 2017 Aug;21(4):732-740. Epub 2016 Aug 26 doi: 10.1007/s10157-016-1327-z. PMID: 27565169
Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer.
Kobayashi S, Ueno M, Ohkawa S, Irie K, Goda Y, Morimoto M
Oncology 2014;87(1):30-9. Epub 2014 Jun 25 doi: 10.1159/000362604. PMID: 24969038

Diagnosis

CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E, Brachet PE, Licaj I, Leconte A, Castera M, Lequesne J, Meriaux E, Bonnet I, Lelaidier A, Clarisse B, Joly F
BMC Cancer 2021 Sep 25;21(1):1054. doi: 10.1186/s12885-021-08758-9. PMID: 34563169Free PMC Article
Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H
Clin Exp Nephrol 2017 Aug;21(4):732-740. Epub 2016 Aug 26 doi: 10.1007/s10157-016-1327-z. PMID: 27565169

Therapy

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T, Yazawa M, Yamamoto R, Okada N, Mori K, Yamada H, Kuwabara T, Yonezawa A, Fujimaru T, Kawano H, Yokoi H, Doi K, Hoshino J, Yanagita M
Int J Clin Oncol 2023 Oct;28(10):1259-1297. Epub 2023 Jun 29 doi: 10.1007/s10147-023-02372-4. PMID: 37382749
Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers.
Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C, Casuscelli J
J Geriatr Oncol 2020 Sep;11(7):1061-1066. Epub 2020 Jun 18 doi: 10.1016/j.jgo.2020.06.012. PMID: 32565147
A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P
J Oncol Pharm Pract 2019 Jun;25(4):875-883. Epub 2018 May 3 doi: 10.1177/1078155218771461. PMID: 29722605
Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H
Clin Exp Nephrol 2017 Aug;21(4):732-740. Epub 2016 Aug 26 doi: 10.1007/s10157-016-1327-z. PMID: 27565169
Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer.
Kobayashi S, Ueno M, Ohkawa S, Irie K, Goda Y, Morimoto M
Oncology 2014;87(1):30-9. Epub 2014 Jun 25 doi: 10.1159/000362604. PMID: 24969038

Prognosis

Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN).
Hsiao W, Li Y, Getz K, Cao L, Krause E, Ramos M, Lee J, Gramatges MM, Rabin KR, Scheurer ME, Aplenc R, Denburg M, Miller TP
Pediatr Blood Cancer 2023 Dec;70(12):e30696. Epub 2023 Sep 30 doi: 10.1002/pbc.30696. PMID: 37776085Free PMC Article
CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E, Brachet PE, Licaj I, Leconte A, Castera M, Lequesne J, Meriaux E, Bonnet I, Lelaidier A, Clarisse B, Joly F
BMC Cancer 2021 Sep 25;21(1):1054. doi: 10.1186/s12885-021-08758-9. PMID: 34563169Free PMC Article
Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers.
Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C, Casuscelli J
J Geriatr Oncol 2020 Sep;11(7):1061-1066. Epub 2020 Jun 18 doi: 10.1016/j.jgo.2020.06.012. PMID: 32565147
A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P
J Oncol Pharm Pract 2019 Jun;25(4):875-883. Epub 2018 May 3 doi: 10.1177/1078155218771461. PMID: 29722605
Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H
Clin Exp Nephrol 2017 Aug;21(4):732-740. Epub 2016 Aug 26 doi: 10.1007/s10157-016-1327-z. PMID: 27565169

Clinical prediction guides

Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers.
Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C, Casuscelli J
J Geriatr Oncol 2020 Sep;11(7):1061-1066. Epub 2020 Jun 18 doi: 10.1016/j.jgo.2020.06.012. PMID: 32565147
A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P
J Oncol Pharm Pract 2019 Jun;25(4):875-883. Epub 2018 May 3 doi: 10.1177/1078155218771461. PMID: 29722605
The impact of repeated cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.
Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H
Eur J Nucl Med Mol Imaging 2017 Aug;44(9):1473-1479. Epub 2017 Mar 23 doi: 10.1007/s00259-017-3681-9. PMID: 28337529
Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H
Clin Exp Nephrol 2017 Aug;21(4):732-740. Epub 2016 Aug 26 doi: 10.1007/s10157-016-1327-z. PMID: 27565169

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...